{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:25:51Z","timestamp":1793787951795,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306600"],"award-info":[{"award-number":["2023YFC2306600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.virol.2026.111091","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:58:37Z","timestamp":1790146717000},"page":"111091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-tumor efficacy of oncolytic herpes simplex viruses constructed by synthetic genomics in a murine colorectal carcinoma model and in human tumor cell lines"],"prefix":"10.1016","volume":"625","author":[{"given":"Han","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiran","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengrui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-0928","authenticated-orcid":false,"given":"Zhihong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-3530","authenticated-orcid":false,"given":"Manli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.111091_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","article-title":"Development of oncolytic viruses for cancer therapy","volume":"237","author":"Abd-Aziz","year":"2021","journal-title":"Translat. Res."},{"key":"10.1016\/j.virol.2026.111091_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/cells10061541","article-title":"Oncolytic herpes simplex virus-based therapies for cancer","volume":"10","author":"Aldrak","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.virol.2026.111091_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2024.12.054","article-title":"Understanding the interplay between ohsv and the host immune system: implications for therapeutic oncolytic virus development","volume":"33","author":"Ayele","year":"2025","journal-title":"Mole. Therapy"},{"key":"10.1016\/j.virol.2026.111091_bib4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.virol.2026.111091_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for bcg-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1375433","article-title":"New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy","volume":"15","author":"Chowaniec","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.virol.2026.111091_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2026.111091_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","article-title":"Single-cell rna-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma","volume":"21","author":"Darmanis","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2026.111091_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2026.111091_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/laban.254","article-title":"Estimation of rat mammary tumor volume using caliper and ultrasonography measurements","volume":"42","author":"Faustino-Rocha","year":"2013","journal-title":"Lab Anim."},{"key":"10.1016\/j.virol.2026.111091_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (t-vec): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers [J]"},{"key":"10.1016\/j.virol.2026.111091_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/mt.2008.240","article-title":"A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer","volume":"17","author":"Fong","year":"2009","journal-title":"Mole. Therapy"},{"key":"10.1016\/j.virol.2026.111091_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/g47\u03b4: first approval","volume":"36","author":"Frampton","year":"2022","journal-title":"biodrugs [j]"},{"key":"10.1016\/j.virol.2026.111091_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2010.020","article-title":"Phase i\/ii study of oncolytic herpes simplex virus nv1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver","volume":"21","author":"Geevarghese","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.virol.2026.111091_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13027-023-00521-y","article-title":"Antiproliferative effects of mesenchymal stem cells carrying newcastle disease virus and lactobacillus casei extract on ct26 cell line: synergistic effects in cancer therapy","volume":"18","author":"Ghorbani Alvanegh","year":"2023","journal-title":"Infect. Agents Cancer"},{"key":"10.1016\/j.virol.2026.111091_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/jvi.38.1.50-58.1981","article-title":"Cloning of herpes simplex virus type 1 sequences representing the whole genome","volume":"38","author":"Goldin","year":"1981","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.111091_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat Rev. Cancer"},{"key":"10.1016\/j.virol.2026.111091_bib18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1089\/hum.2006.17.1241","article-title":"Efficacy of oncolytic herpesvirus nv1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells","volume":"17","author":"Gutermann","year":"2006","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.virol.2026.111091_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41434-020-00205-x","article-title":"Antitumor effects of il-12 and gm-csf co-expressed in an engineered oncolytic hsv-1","volume":"28","author":"Kim","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2026.111091_bib20","first-page":"961","article-title":"Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses","volume":"50","author":"Kimata","year":"2003","journal-title":"Hepato-Gastroenterol."},{"key":"10.1016\/j.virol.2026.111091_bib21","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.3390\/cancers12123514","article-title":"Hsv-1 oncolytic viruses from bench to bedside: an overview of current clinical trials","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers [J]"},{"key":"10.1016\/j.virol.2026.111091_bib22","first-page":"25","article-title":"Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies","volume":"32","author":"Konety","year":"2025","journal-title":"Canadian J. Urol."},{"key":"10.1016\/j.virol.2026.111091_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","article-title":"Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review","volume":"15","author":"Kumar","year":"2023","journal-title":"World J. Gastro Surg."},{"key":"10.1016\/j.virol.2026.111091_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300445","article-title":"Oncolytic viruses in cancer immunotherapy","volume":"7","author":"Li","year":"2024","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.virol.2026.111091_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.virol.2026.111091_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.virol.2026.111091_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41421-021-00249-2","article-title":"Sars-cov-2 cell tropism and multiorgan infection","volume":"7","author":"Liu","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.virol.2026.111091_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4251\/wjgo.v15.i2.240","article-title":"\"Cold\" colorectal cancer faces a bottleneck in immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.virol.2026.111091_bib30","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1080\/10717544.2018.1534895","article-title":"Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins","volume":"25","author":"Liu","year":"2018","journal-title":"Drug Delivery."},{"key":"10.1016\/j.virol.2026.111091_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from globocan","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut [J]"},{"key":"10.1016\/j.virol.2026.111091_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1359725","article-title":"Mechanism of action of nadofaragene firadenovec-vncg","volume":"14","author":"Narayan","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell [J]"},{"key":"10.1016\/j.virol.2026.111091_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1082797","article-title":"Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy","volume":"13","author":"Omole","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.virol.2026.111091_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0166-0934(94)90096-5","article-title":"An improved method for cloning portions of the repeat regions of herpes-simplex virus type-1","volume":"46","author":"Perng","year":"1994","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.virol.2026.111091_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.it.2015.11.008","article-title":"Neutrophils in the tumor microenvironment","volume":"37","author":"Powell","year":"2016","journal-title":"Trend Immunol."},{"key":"10.1016\/j.virol.2026.111091_bib37","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.virol.2026.111091_bib38","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3390\/cells14242006","article-title":"Oncolytic virotherapy in colorectal cancer: mechanistic insights, enhancer strategies, and translational combinations","volume":"14","author":"Salameh","year":"2025","journal-title":"Cells [J]"},{"key":"10.1016\/j.virol.2026.111091_bib39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.bjc.6602783","article-title":"Side effects during chemotherapy predict tumour response in advanced colorectal cancer","volume":"93","author":"Schuell","year":"2005","journal-title":"British J. Cancer"},{"key":"10.1016\/j.virol.2026.111091_bib40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/biomedicines13030642","article-title":"Advances in targeted and chemotherapeutic strategies for colorectal cancer: current insights and future directions","volume":"13","author":"Shaham","year":"2025","journal-title":"Biomedicines [J]"},{"key":"10.1016\/j.virol.2026.111091_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/cgt.2011.49","article-title":"Vesicular stomatitis virus as a treatment for colorectal cancer","volume":"18","author":"Stewart","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.virol.2026.111091_bib43","article-title":"An updated review of hsv-1 infection-associated diseases and treatment, vaccine development, and vector therapy application","volume":"15","author":"Su","year":"2024","journal-title":"Virulence [J]"},{"key":"10.1016\/j.virol.2026.111091_bib44","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-a Cancer J. Clinicians [J]"},{"key":"10.1016\/j.virol.2026.111091_bib45","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.ymthe.2025.07.034","article-title":"Oncolytic hsv and cancer drug interactions: current clinical status and future directions","volume":"33","author":"V\u00e1zquez-Arregu\u00edn","year":"2025","journal-title":"Mole. Therapy"},{"key":"10.1016\/j.virol.2026.111091_bib46","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.cell.2022.06.046","article-title":"Synthetic chromosomes, genomes, viruses, and cells","volume":"185","author":"Venter","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.virol.2026.111091_bib47","article-title":"Survival rate of colorectal cancer in China: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121576","article-title":"Dissecting the heterogeneities of the tumor microenvironment between metastatic and nonmetastatic primary colorectal cancer patients by single-cell rna sequencing","volume":"320","author":"Wang","year":"2023","journal-title":"Life Sci. J."},{"key":"10.1016\/j.virol.2026.111091_bib49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13046-025-03358-y","article-title":"Viral expression of ne\/ppe enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting tam m1 polarization to reverse insufficient effector memory\/effector cd8+ t cell infiltration","volume":"44","author":"Wang","year":"2025","journal-title":"J. Experi. Clin. Cancer Res."},{"key":"10.1016\/j.virol.2026.111091_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1186\/s12885-025-15138-0","article-title":"Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from globocan","volume":"25","author":"Wu","year":"2025","journal-title":"Bmc Cancer [J]"},{"key":"10.1016\/j.virol.2026.111091_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib52","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/acssynbio.4c00360","article-title":"Efficient strategy for synthesizing vector-free and oncolytic herpes simplex type 1 viruses","volume":"13","author":"Xiao","year":"2024","journal-title":"ACS Synth Biol."},{"key":"10.1016\/j.virol.2026.111091_bib53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.virs.2025.11.002","article-title":"Oncolytic hsv-1 expressing gm-csf and il-12 enhances anti-tumor efficacy in immunocompetent murine melanoma model","volume":"40","author":"Xiao","year":"2025","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virol.2026.111091_bib54","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","article-title":"An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ","volume":"30","author":"Ye","year":"2022","journal-title":"Mole. Therapy"},{"key":"10.1016\/j.virol.2026.111091_bib55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13024-017-0179-7","article-title":"Anterograde monosynaptic transneuronal tracers derived from herpes simplex virus 1 strain h129","volume":"12","author":"Zeng","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.virol.2026.111091_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.198979","article-title":"Construction of an il12 and cxcl11 armed oncolytic herpes simplex virus using the crispr\/cas9 system for colon cancer treatment","volume":"323","author":"Zhang","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2026.111091_bib57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-egfr therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Experi. Clin. Cancer Res."},{"key":"10.1016\/j.virol.2026.111091_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1525940","article-title":"Advanced progress in the genetic modification of the oncolytic hsv-1 virus","volume":"14","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102020","article-title":"The oncolytic virus vt1092m and an anti-pd-l1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model","volume":"46","author":"Zhu","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.virol.2026.111091_bib60","article-title":"Engineering hsv-1 for oncolytic therapy: from molecular entry mechanisms to retargeting strategies","volume":"13","author":"Zou","year":"2026","journal-title":"Genes Dis."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226003077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226003077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:39:20Z","timestamp":1793785160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":60,"alternative-id":["S0042682226003077"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.111091","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumor efficacy of oncolytic herpes simplex viruses constructed by synthetic genomics in a murine colorectal carcinoma model and in human tumor cell lines","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.111091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111091"}}